Summary
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
History
Quotient Biodiagnostics was founded in 1976 in the United Kingdom. They specialize in producing a wide array of diagnostic tests that are clinically proven to help accurately diagnose and manage a number of medical conditions. Their tests are used in many settings, including primary care, specialty care, acute care, and extended care.
Mission
Our mission is to help healthcare professionals and their patients access reliable, cost-effective diagnostics that enable them to make informed decisions and receive the best possible care.
Vision
We strive to become the leading provider of reliable, accurate, and cost-effective diagnostics to healthcare professionals and their patients.
Key Team
Ms. Vittoria Bonasso (Head of Fin., Group Controller & Principal Accounting Officer)
Dr. Christine Ginocchio (Chief Scientific & Medical Officer)
Dr. Michael Hausmann (Chief Technology Officer)
Ms. Hyatt Antognini-Amin (Head of Corp. Communications)
Ms. Viviane Montarnal (Head of Legal Affairs & Compliance)
Mr. Christian Albrich (Chief People Officer)
Mr. Esteban Uriarte (Chief Manufacturing Operations Officer)
Recognition and Awards
Quotient Biodiagnostics’ innovative tests have been recognized with the following awards: HM Queen’s Awards for Enterprise, The International Diagnostics Award, and The British Inventors’ Award.
References
